About this Research Topic
Adoptive cell therapies (ACT), in which genetically modified immune cells are transferred to cancer patients as a therapeutic modality are now approved for several hematologic malignancies. However, only a single cell therapy is approved for any solid tumor, sipuleucel-T for prostate cancer, which was approved over 10 years ago and is barely used. This situation will likely change in the next year with the expected approval of ACT with unmodified tumor-infiltrating lymphocytes (TIL) for treatment-refractory metastatic melanoma.
The goal of this research topic is to present an array of Original Research articles, covering some of the major topics in cell therapies for solid tumors. The range of issues is large but mostly fits into the following categories:
1. Clinical trials using TIL for solid tumors – e.g. melanoma, lung cancer, HPV+ cancers are the most frequently studied but others are currently underway.
2. Predictive features of TIL or CAR-T products – cell subsets or clinical features predicting response; this could be in humans or in mouse studies.
3. Immune characterization of cell products - this could include studies of the differentiation states of CAR-T or TIL during ex vivo growth and how those states could be manipulated to optimize the cell products.
4. Trials of CAR-T products for solid tumors.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic
The goal of this research topic is to present an array of Original Research articles, covering some of the major topics in cell therapies for solid tumors. The range of issues is large but mostly fits into the following categories:
1. Clinical trials using TIL for solid tumors – e.g. melanoma, lung cancer, HPV+ cancers are the most frequently studied but others are currently underway.
2. Predictive features of TIL or CAR-T products – cell subsets or clinical features predicting response; this could be in humans or in mouse studies.
3. Immune characterization of cell products - this could include studies of the differentiation states of CAR-T or TIL during ex vivo growth and how those states could be manipulated to optimize the cell products.
4. Trials of CAR-T products for solid tumors.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic
Keywords: TIL, tumor infiltrating lymphocytes, Adoptive cell therapy, CAR-T, engineered cells
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
